Journal
BIOMEDICINES
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9040422
Keywords
ischemic heart disease; ischemia; reperfusion injury; secretory leukocyte protease inhibitor (SLPI); cardioprotection; post-ischemic treatment
Categories
Funding
- Thailand Research Fund
- Chiang Mai University [RSA6280025]
- Royal Golden Jubilee Ph.D. Program [PHD/0087/2561]
- Franco-Thai PHC mobility program
- University of Phayao
Ask authors/readers for more resources
This study demonstrates that post-ischemic treatment with rhSLPI can significantly reduce infarct size, LDH and CK-MB activity, inflammatory cytokines, and protein carbonyl levels, as well as improve cardiac function. The cardioprotective effect of rhSLPI is associated with the attenuation of p38 MAPK phosphorylation, Bax, caspase-3 and -8 protein levels, and enhancement of pro-survival kinase Akt and ERK1/2 phosphorylation.
Myocardial ischemia/reperfusion (I/R) injury is a major cause of mortality and morbidity worldwide. Among factors contributing to I/R injury, proteolytic enzymes could also cause cellular injury, expand the injured area and induce inflammation, which then lead to cardiac dysfunction. Therefore, protease inhibition seems to provide therapeutic benefits. Previous studies showed the cardioprotective effect of secretory leukocyte protease inhibitor (SLPI) against myocardial I/R injury. However, the effect of a post-ischemic treatment with SLPI in an in vivo I/R model has never been investigated. In the present study, recombinant human (rh) SLPI (rhSLPI) was systemically injected during coronary artery occlusion or at the onset of reperfusion. The results show that post-ischemic treatment with rhSLPI could significantly reduce infarct size, Lactate Dehydrogenase (LDH) and Creatine kinase-MB (CK-MB) activity, inflammatory cytokines and protein carbonyl levels, as well as improving cardiac function. The cardioprotective effect of rhSLPI is associated with the attenuation of p38 MAPK phosphorylation, Bax, caspase-3 and -8 protein levels and enhancement of pro-survival kinase Akt and ERK1/2 phosphorylation. In summary, this is the first report showing the cardioprotective effects against myocardial I/R injury of post-ischemic treatments with rhSLPI in vivo. Thus, these results suggest that SLPI could be used as a novel therapeutic strategy to reduce myocardial I/R injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available